IBRX 6-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims -- Hagens Berman

San Francisco, California--(Newsfile Corp. - May 20, 2026) - ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026.

The lawsuit follows news that the FDA sent a warning letter to the company concerning claims made by its executive chairman and Chief Scientific and Medical Officer (Dr. Patrick Soon-Shiong) regarding ImmunityBio's lead biologic product (Anktiva), which the FDA said were misleading efficacy claims.

This news drove the price of ImmunityBio shares down over 21% on March 24, 2026.

The developments have prompted national shareholders rights firm Hagens Berman to investigate claims that ImmunityBio violated the federal securities laws.

The firm urges investors in ImmunityBio who suffered significant losses to submit your losses now. The firm also encourages witnesses who may be able to assist in the investigation to contact its attorneys.

DEEP DIVE ANALYIS: Visit Hagens Berman's dedicated IBRX case page: www.hbsslaw.com/cases/immunitybio, or view our latest video summary of the allegations:

Cannot view this video? Visit:
https://www.youtube.com/watch?v=e1pGV9KiS8U

Class Period: Jan. 19, 2026 - Mar. 24, 2026
Lead Plaintiff Deadline: May 26, 2026
Visit: www.hbsslaw.com/investor-fraud/ibrx
Contact the Firm Now: [e-mail]
844-916-0895

ImmunityBio, Inc. (IBRX) Securities Class Action:

ImmunityBio is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases.

The company's Anktiva is an FDA-approved immunotherapy used with Bacillus Calmette-Guérin ("BCG") to treat non-muscle invasive bladder cancer ("NMIBC").

The lawsuit is focused on the propriety of ImmunityBio's claims about Anktiva's efficacy for treating other forms of cancer.

On January 19, 2026, a direct-to-consumer podcast ("Is the FDA BLOCKING Life Saving Cancer Treatments?") aired, featuring Soon-Shiong. During the podcast, he said in part that, while Anktiva is approved for bladder cancer, "it actually can treat all cancers." Soon-Shiong made other questionable claims about Anktiva, which together were flagged by the FDA as misleading.

Schreibe Deinen Kommentar